ALLO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
-100.0%
4.6M
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
4.6M
0
0
0
Operating Expenses
54.8M
+6.3%
51.6M
+11.9%
46.1M
+8.7%
42.4M
-5.6%
44.9M
R&D
41.9M
+36.5%
30.7M
-4.0%
32.0M
+11.8%
28.6M
-8.1%
31.2M
SG&A
12.9M
-38.3%
20.8M
+47.9%
14.1M
+2.3%
13.8M
+0.3%
13.7M
Operating Income
-54793000
-16.8%
-46920000
-1.8%
-46092000
-8.7%
-42404000
+5.6%
-44901000
EBITDA
-52207000
-17.9%
-44275000
-2.4%
-43223000
-9.9%
-39347000
+5.9%
-41804000
Net Income
-50369000
-18.0%
-42677000
-0.2%
-42607000
-9.8%
-38810000
+6.3%
-41400000
EPS (Basic)
$-0.15
-15.4%
$-0.13
+27.8%
$-0.18
-5.9%
$-0.17
+10.5%
$-0.19
EPS (Diluted)
$-0.15
-15.4%
$-0.13
+27.8%
$-0.18
-5.9%
$-0.17
+10.5%
$-0.19
Shares (Diluted)
346.1M
+5.2%
328.9M
+36.9%
240.3M
+6.2%
226.2M
+1.9%
222.0M
Allogene Therapeutics (ALLO) — Financials